The wild-type recipient mice were s.c. injected with B16-MO5 melanoma cells, then CsA-treated or untreated OVA257-264-specific wild-type CD8+ CTLs were i.v. injected into these recipient mice at day 9. Here, CD8A is linked to melanoma.